DIA
SCLN

Denver Investment Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Denver Investment Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,678
Closed -$139K – 484
2016
Q2 		$139K Sell
10,678
-2,240
-17% -$29.4K 0.01% 422
2016
Q1 		$142K Sell
12,918
-14,396
-53% -$128K 0.01% 416
2015
Q4 		$251K Sell
27,314
-3,102
-10% -$26K 0.01% 413
2015
Q3 		$211K Sell
30,416
-1,047
-3% -$8.97K 0.01% 456
2015
Q2 		$309K Sell
31,463
-8,592
-21% -$78.3K 0.01% 419
2015
Q1 		$355K Buy
40,055
+11,666
+41% +$92.9K 0.01% 444
2014
Q4 		$249K Sell
28,389
-12,910
-31% -$104K 0.01% 512
2014
Q3 		$285K Sell
41,299
-4,473
-10% -$26.8K 0.01% 445
2014
Q2 		$241K Sell
45,772
-16,941
-27% -$82.4K 0.01% 501
2014
Q1 		$285K Buy
62,713
+43,971
+235% +$212K 0.01% 477
2013
Q4 		$94 Hold
18,742
– – ﹤0.01% 554
2013
Q3 		$95K Buy
18,742
+4,115
+28% +$22.9K ﹤0.01% 562
2013
Q2 		$73K Buy
+14,627
New +$69.6K ﹤0.01% 538

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Denver Investment Advisors's SCLN Position: Q3 2016 in Review

Denver Investment Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2016, closing a stake of 10,678 shares — an estimated $139K sold.

Denver Investment Advisors first reported a position in SCLN in Q2 2013 and held it in 13 quarters. The position peaked at $355K in Q1 2015. 151 funds tracked by Wall St. Rank hold SCLN as of Q3 2016.

  • Denver Investment Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Denver Investment Advisors sold 10,678 Sciclone Pharmaceuticals Inc shares in Q3 2016, an estimated $139K.
  • Denver Investment Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 13 quarters.
  • Denver Investment Advisors's Sciclone Pharmaceuticals Inc position peaked at $355K in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2016.

Based on Denver Investment Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.